Accelerator Fund boon to research

Sometimes, promising scientific findings aren’t enough, by themselves. Life-science researchers at Harvard who’ve made new inventions with applied and commercial potential are often disappointed to learn that pharmaceutical, venture capital, or biotech firms aren’t interested in their work — and not because a discovery lacks merit. Instead, the glitch may be that the research hasn’t progressed far enough to establish proof-of-principle, which is imperative for industry to make a forward-looking decision to invest significant resources and develop it for commercial application.read more

Read the whole article on Harvard Science

More from Harvard Science